Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 6/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 10/20 | 0.47 |
| ▸ | ADK | P55263 | 5/20 | 0.45 |
| ▸ | RAPGEF3 | O95398 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17111271 | 0.96 | PRMT5 (0.45) | PRMT5METTL3ADKRAPGEF3 | |
| SCHEMBL17106819 | 0.90 | PRMT5 (0.48) | PRMT5METTL3ADKRAPGEF3 | |
| SCHEMBL17106763 | 0.90 | ADK (0.41) | PRMT5METTL3ADK | |
| SCHEMBL17106721 | 0.89 | PRMT5 (0.38) | PRMT5METTL3ADK | |
| SCHEMBL17106786 | 0.89 | ADK (0.47) | PRMT5METTL3ADK | |
| SCHEMBL17111225 | 0.89 | ADK (0.47) | PRMT5METTL3ADK | |
| SCHEMBL17106848 | 0.89 | METTL3 (0.47) | PRMT5METTL3ADK | |
| SCHEMBL17111224 | 0.89 | ADK (0.47) | PRMT5METTL3ADK | |
| SCHEMBL17111262 | 0.89 | METTL3 (0.47) | PRMT5METTL3ADK | |
| SCHEMBL17111234 | 0.89 | METTL3 (0.47) | PRMT5METTL3ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-01-04 | — | — | US | disclosed |
| US-9777035-B2 | 4′-substituted nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-10-03 | — | — | US | disclosed |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002366-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | PRMT5 151/4885METTL3 624/4885ADK 731/4885 |
| US-20150274767-A1 | 4'-SUBSTITUTED NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | DUT, HPRT1, RNGTT | PRMT5 151/4885METTL3 624/4885ADK 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.